Phase 2 Lung Cancer Trial, Recruiting NCT06538012 Sponsor: Essen Biotech Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06538012
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 16 and 90 years old
  • You have been diagnosed with lung cancer (primary, returned, or spread to other parts of the body), confirmed by a tissue test
  • You are expected to live for more than 3 months
  • You are able to carry out some daily activities (your doctor can assess this using standard scoring tools)
  • Standard treatments have not worked for you, or no standard treatments are available for your condition
  • You have a tumor area that can be safely biopsied or removed, or fluid in your body containing cancer cells that can be used for treatment
  • You have at least one measurable tumor that can be tracked during the trial
  • Your blood test results taken within 7 days before joining show that your white blood cells, infection-fighting cells, clotting ability, kidney function, and liver function are all within acceptable levels (your doctor will check these)
  • There are no medical reasons preventing you from having a biopsy or minor surgery
  • If you could become pregnant, you must be willing to use highly effective contraception from when you sign consent until at least 1 year after a specific part of the treatment is completed
  • Any previous cancer treatments (such as radiotherapy, chemotherapy, or biological therapies) must have stopped at least 28 days before the tissue collection step
  • You are able to understand and sign the consent form
  • You are able to attend follow-up visits and follow the study requirements

Who may not be able to join:

  • You need regular steroid medication (such as prednisone) at a dose higher than 15mg per day, or you have an autoimmune condition requiring immune-suppressing treatment
  • Your lung function tests show significantly reduced breathing capacity (confirm with trial site)
  • You have serious heart problems, such as severe heart failure, very low blood pressure, uncontrolled chest pain, a weak pumping function, or serious heart rhythm problems
  • You have HIV, active hepatitis B or C, or syphilis
  • You have a serious physical or mental health condition
  • You currently have an active infection in your body that requires treatment, or there is evidence of infection in your blood or on scans
  • You have received or are currently receiving other cancer treatments, medicines, or therapies within the past month
  • You have a known allergy to substances similar to those used in cell-based therapies
  • You previously had a serious (Grade 3 or higher) immune-related side effect from immunotherapy
  • You still have significant side effects from a previous cancer treatment that have not fully resolved (minor issues like hair loss may be excepted — confirm with trial site)
  • You are pregnant or breastfeeding
  • You have had an organ transplant, a stem cell transplant using donor cells, or kidney dialysis
  • The research team considers you to have another serious condition or another reason that makes joining the trial unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Essen Biotech
Registry
ClinicalTrials.gov
Start date
20 August 2024
Est. completion
10 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov